Skip to content

    RHYTHM PHARMACEUTICALS (RYTM) stock price & financials

    View RYTM earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+4.8% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $33.25M
    $41.83M
    $32.70M
    $48.50M
    $51.30M
    +54.3%
    $57.25M
    +36.9%
    $60.11M
    +83.8%
    $71.25M
    +46.9%
    Strengthening
    Operating Profit
    -$43.88M
    -$41.25M
    -$47.00M
    -$45.30M
    -$52.65M
    -20.0%
    -$47.06M
    -14.1%
    -$52.36M
    -11.4%
    -$48.55M
    -7.2%
    Weakening
    Net Profit
    -$43.64M
    -$43.33M
    -$49.50M
    -$46.63M
    -$52.90M
    -21.2%
    -$47.51M
    -9.6%
    -$55.64M
    -12.4%
    -$49.30M
    -5.7%
    Weakening
    EPS
    $-0.73
    $-0.81
    $-0.75
    $-0.82
    -12.3%
    $-0.83
    -2.5%
    $-0.73
    +2.7%
    Stable
    Other Income
    -$100.0K
    -$2.16M
    -$2.41M
    -$999.0K
    -$140.0K
    -40.0%
    -$473.0K
    +78.1%
    -$2.73M
    -13.2%
    -$302.0K
    +69.8%
    Strengthening
    Interest
    $5.24M
    $6.00M
    $5.41M
    $5.82M
    $4.74M
    -9.5%
    $4.62M
    -23.1%
    $4.58M
    -15.3%
    $4.54M
    -22.0%
    Weakening
    Depreciation
    Profit before Tax
    -$43.98M
    -$43.42M
    -$49.42M
    -$46.30M
    -$52.79M
    -20.0%
    -$47.54M
    -9.5%
    -$55.09M
    -11.5%
    -$48.85M
    -5.5%
    Weakening
    MarginsOPM
    -132.0%
    -98.6%
    -143.7%
    -93.4%
    -102.6%
    +22.2%
    -82.2%
    +16.6%
    -87.1%
    +39.4%
    -68.1%
    +27.0%
    Strengthening
    Tax
    0.8%
    0.2%
    -0.2%
    -0.7%
    -0.2%
    -126.9%
    0.1%
    -65.0%
    -1.0%
    -518.8%
    -0.9%
    -24.7%
    Weakening
    ReturnsROIC
    3.0%
    3.0%
    3.4%
    3.2%
    3.6%
    +21.2%
    3.3%
    +9.6%
    3.8%
    +12.4%
    3.4%
    +5.7%
    Strengthening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$49.54M$62.29M$100.85M$59.25M$127.68M$60.08M$89.14M$54.30M$65.61M
    Short-Term Investments
    Total Current Assets$258.69M$302.40M$181.67M$308.39M$354.24M$308.27M$374.20M$466.92M$426.56M
    Net PP&E$4.38M$5.72M$5.00M$4.33M$3.38M$2.12M$4.11M$4.15M$2.92M
    Goodwill
    Intangibles$4.66M$7.88M$7.03M$6.17M$5.32M$4.89M
    Total Assets$260.21M$308.52M$187.07M$329.52M$382.48M$332.75M$392.27M$480.20M$437.27M
    LiabilitiesTotal Current Liabilities$13.58M$24.42M$17.99M$43.43M$39.81M$55.20M$115.52M$105.94M$123.59M
    Short-Term Debt$1.54M$7.30M$12.70M
    Long-Term Debt$106.14M$108.27M$100.89M$93.40M
    Long-Term Leases$1.95M$1.26M$490.0K$3.94M$3.34M$2.98M
    Total Liabilities$13.95M$27.50M$20.55M$45.37M$118.22M$162.99M$227.72M$210.17M$219.97M
    EquityCommon Stock & APIC$34.0K$44.0K$44.0K$50.0K$56.0K$59.0K$61.0K$67.0K$69.0K
    Retained Earnings-$184.60M-$325.33M-$459.33M-$528.94M-$710.06M-$894.74M-$1.16B-$1.35B-$1.46B
    Total Equity$246.26M$281.02M$166.53M$284.15M$264.26M$169.76M$21.73M$139.07M$102.98M
    HighlightsNet Cash / (Debt)-$20.67M-$53.88M-$40.49M

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$62.06M-$122.75M-$121.98M-$146.00M-$173.43M-$136.16M-$113.88M-$115.67M-$105.35M
    Cash from Investing-$87.15M-$27.97M$158.53M-$62.16M$28.03M-$5.67M-$48.17M-$137.15M-$144.94M
    Cash from Financing$164.69M$163.47M$2.01M$166.48M$213.83M$74.37M$191.24M$217.96M$179.79M
    SummaryCapital Expenditure-$722.0K-$3.38M-$214.0K-$434.0K-$281.0K-$47.0K$0-$953.0K
    Free Cash Flow-$62.78M-$126.14M-$122.19M-$146.44M-$173.71M-$136.20M-$113.88M-$116.63M
    FCF Margin-4642.9%-734.9%-175.9%-87.5%-61.5%

    Ratios